James G Kublin
Overview
Explore the profile of James G Kublin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
3822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi N, et al.
EClinicalMedicine
. 2025 Feb;
80:103054.
PMID: 39902315
Background: With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008...
2.
Wilson G, Church L, Kelley C, Robinson S, Lu Y, Furch B, et al.
J Infect Dis
. 2024 Dec;
PMID: 39671174
Utilizing transiently transfected cell lines could significantly reduce manufacturing timelines for protein subunit vaccines. This trial compared safety and immunogenicity of human immunodeficiency virus (HIV) envelope CH505TF gp120 vaccines produced...
3.
Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D, et al.
Nat Commun
. 2024 Nov;
15(1):9785.
PMID: 39532861
Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels...
4.
Huang Y, Alam S, Andersen-Nissen E, Carpp L, Dintwe O, Flach B, et al.
Viruses
. 2024 Sep;
16(9).
PMID: 39339842
Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An...
5.
Church E, Bishop E, Fiore-Gartland A, Yu K, Chang M, Jones R, et al.
Immunohorizons
. 2024 Sep;
8(9):695-711.
PMID: 39283647
Cutaneous mycobacterial infections cause substantial morbidity and are challenging to diagnose and treat. An improved understanding of the dermal immune response to mycobacteria may inspire new therapeutic approaches. We conducted...
6.
Zhang B, Fong Y, Fintzi J, Chu E, Janes H, Kenny A, et al.
Nat Commun
. 2024 Sep;
15(1):7954.
PMID: 39261482
In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection...
7.
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, et al.
EBioMedicine
. 2024 Sep;
108:105320.
PMID: 39236556
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based...
8.
Janes H, Fisher L, Kee J, Parameswaran L, Goepfert P, Falsey A, et al.
J Infect Dis
. 2024 Sep;
230(6):1384-1389.
PMID: 39225478
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in...
9.
Vielot N, Kelly N, Ludema C, Rosenberg M, Brown E, Janes H, et al.
Vaccine
. 2024 Aug;
42(23):126237.
PMID: 39182315
Background: The introduction of vaccines during the COVID-19 pandemic provided an opportunity to slow transmission of SARS-CoV-2, but initial uptake of COVID-19 vaccination was slow. We analyzed data from a...
10.
Gray G, Mngadi K, Lavreys L, Nijs S, B Gilbert P, Hural J, et al.
Lancet Infect Dis
. 2024 Jul;
24(11):1201-1212.
PMID: 39038477
Background: HIV type 1 (HIV-1) remains a global health concern, with the greatest burden in sub-Saharan Africa. Despite 40 years of research, no vaccine candidate has shown durable and protective...